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In this issue of Cancer Cell, Skrtic et al. demonstrate that inhibition of mitochondrial ribosomes with tigecy-
cline, a known antimicrobial, selectively kills leukemia cells. This finding highlights the metabolic suscepti-
bility of leukemia cells to mitochondrial translational inhibition and identifies a compound with significant
efficacy in an in vivo preclinical model.Advances in cancer genomics are
providing tremendous insights into the
genetic basis of acute myeloid leukemia
(AML), but the development of novel
pharmacologic therapies has not pro-
ceeded as rapidly (Ley et al., 2010; Mardis
et al., 2009). The identification of novel
mutations, epigenetic dysregulation, and
aberrant gene expression patterns has
yielded profound insights into the patho-
genesis of AML. However, many of the
molecular lesions highlighted by these
studies, such as loss-of-function muta-
tions in tumor suppressor genes, are not
straightforward therapeutic targets. An
alternative strategy for the identification
of therapeutic targets is to identify tumor
cell dependencies that are not necessarily
directly related to somatically mutated
genes through unbiased screens.
In this issue of Cancer Cell, Skrtic et al.
(2011) performed a chemical screen using
two AML cell lines and FDA-approved
drugs in the hopes of facilitating rapid
clinical translation of any findings. Salino-
mycin, recently reported to target breast
cancer stem cells, was a top hit. The
next hit was tigecycline, a broad-spec-
trum antibiotic currently in clinical use. In
validation studies, tigecycline induced
cell death in a panel of murine and human
leukemia cell lines. Importantly, tigecy-
cline showed antileukemia selectivity for
13 out of 20 primary AML patient samples
relative to normal hematopoietic cells.
Both CD34+CD38- cells, which are en-
riched for leukemic stem cells, and the
bulk leukemia cell population was sensi-
tive to tigecycline.
To identify the mechanism whereby
tigecycline inhibits the viability of eukary-
otic cells, the authors performed a
genome-wide haploinsufficiency profiling(HIP) screen in yeast (Giaever et al.,
1999). Interestingly, yeast grown under
respiratory conditions, in which oxidative
phosphorylation is used for energy pro-
duction, were sensitized for tigecycline
relative to yeast grown in rich media
favoring glycolysis. In the HIP screen,
yeast strains haploinsufficient for pro-
teins involved in mitochondrial ribo-
somes were most potently sensitized to
tigecycline treatment, a result that was
also replicated for chloramphenicol, a
known inhibitor of both mitochondrial
and bacterial translation. The sensitivity
of both mitochondrial and bacterial ribo-
somes to tigecycline treatment highlights
the common origin of mitochondrial and
bacterial ribosomes according to the
endosymbiotic hypothesis, which posits
that mitochondria are descendants from
bacterial ancestors that survived endo-
cytosis in eukaryotic cells (Gray et al.,
2001). Hence, the development of
tigecycline for inhibition of prokaryotic
ribosomes relative to mammalian cyto-
solic ribosomes may have optimized the
molecule for selective inhibition of mito-
chondrial ribosomes as well.
Exploring the effects of tigecycline
on mitochondrial ribosome function, the
authors found that tigecycline treatment
preferentially inhibited the translation of
proteins synthesized in mitochondria
relative to proteins translated by cytosolic
ribosomes. Moreover, the pharmacologic
effects of tigecycline on leukemia cells
could also be achieved by genetic inhibi-
tion of mitochondrial translation. Using
RNA interference to knock down expres-
sion of themitochondrial elongation factor
Tu (EF-Tu), which is needed to transport
aminoacyl-tRNAs to the mitochondrial
ribosome, mimicked the selective effectCancer Cell 20, Nof tigecycline on leukemic cells, indepen-
dently demonstrating a previously unrec-
ognized enhanced dependency of leu-
kemic cells for mitochondrial protein
synthesis.
Because the mitochondrial translation
machinery is also essential for normal
cells, the authors searched for differences
between leukemic and normal cell mito-
chondria that could explain the higher
sensitivity of leukemic cells for tigecy-
cline. Compared with normal cells, leu-
kemia cells were found to have a larger
mitochondrial mass, a greater mitochon-
drial DNA copy number, and a higher
rate of oxygen consumption. The reason
for these findings remains to be eluci-
dated, but leukemic cells may need
greater energy production to support
a higher growth and proliferation rate.
Mitochondria generate adenosine-
triphosphate (ATP) through oxidative
phosphorylation. This process takes
place in protein complexes along the
respiratory chain of the mitochondrial
membrane, building up an electro-
chemical proton gradient that generates
the mitochondrial membrane potential.
Administration of tigecycline to leukemic
cells, but not normal cells, disrupted
the membrane potential in an oxygen-
dependent manner. The authors further
demonstrated that protein complexes in
the respiratory chain translated by mito-
chondrial ribosomes were predominantly
suppressed following tigecycline treat-
ment, suggesting that the lower oxygen
consumption is a consequence of the
inhibition of mitochondrial protein syn-
thesis, rather than a direct inhibition of
the respiratory chain.
The finding that AML cells are hyper-
sensitive to inhibition of mitochondrialovember 15, 2011 ª2011 Elsevier Inc. 555
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Previewstranslation adds to our understanding
of cancer cellular metabolism. While
Skrtic et al. describe a dependency for
ribosomal translation and oxidative
phosphorylation in leukemia cells, the
Warburg hypothesis, a cornerstone of
cancer cellular metabolism, postulates
that cancer cells, unlike normal cells,
favor glycolysis for energy production,
even under aerobic conditions (Warburg,
1956). This reprogramming of energy
metabolism in cancer cells is now consid-
ered to be a distinct hallmark of cancer
cells (Hanahan and Weinberg, 2011; Hsu
and Sabatini, 2008; Luo et al., 2009). The
shift in cancer cell metabolism termed
‘‘aerobic glycolysis’’ may be partially an
adaptation to lower oxygen levels in
tumors, but may also be a direct con-
sequence of activation of certain onco-
genes such as MYC and RAS (Hsu and
Sabatini, 2008). In leukemia, inhibition of
fatty acid oxidation was recently shown
to sensitize leukemia cells to apoptosis
induction, but whether this finding is
linked to pathways affected by tigecycline
remains to be elucidated (Samudio et al.,
2010). The full relationship between
dependencies on mitochondrial metabo-556 Cancer Cell 20, November 15, 2011 ª20lism and glycolytic flux in leukemia cells
remains to be determined, but both repre-
sent attractive therapeutic targets for the
treatment of cancer.
Tigecycline is an FDA-approved drug
with known pharmacokinetics and
toxicity, facilitating preclinical studies.
The authors administered the drug to
mice engrafted with primary AML cells
and found a reduction in the leukemic
burden relative to controls, which demon-
strates that AML cells are therapeutically
accessible in vivo. Interestingly, com-
bining tigecycline with daunarubicin,
a cytotoxic drug in clinical use for AML,
had an additive or synergistic antileu-
kemic effect, suggesting that combining
the two should be considered for future
clinical trials. Similar results were ob-
tained for the combination of tigecycline
with Ara-C, another cytotoxic chemother-
apeutic agent in routine use for the treat-
ment of AML. Since tigecycline is already
used in patients as an antimicrobial, and
the toxicity profile is known, clinical trials
in AML could be initiated expeditiously
to determine the efficacy of tigecycline
for the treatment of this challenging
disease.11 Elsevier Inc.REFERENCES
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Constitutive activation of NF-kB signaling can promote oncogenesis, providing a rationale for anticancer
strategies that inhibit NF-kB signaling. Two recent publications in Genes & Development provide evidence
that, in contexts where prosurvival signals derive from other oncogenes, NF-kB activity instead enhances
sensitivity to cytotoxic chemotherapy, thereby exerting a tumor-suppressor function.The nuclear factor-kB (NF-kB) signaling
cascade is a major transducer of external
signals, controlling the expression of
a broad range of genes involved in cellsurvival, growth, stress response, and
inflammation (Hayden and Ghosh, 2008).
NF-kB signaling is tightly regulated and
aberrant activation of this pathway hasbeen associated with the pathogenesis
of solid tumors (Ben-Neriah and Karin,
2011). Recent studies have shown that B
cell lymphomas frequently harbor genetic
